{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-024430","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2024-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.311039+00:00","generated_at":"2026-06-01T03:20:26.134902+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cocrystal Pharma reports CC-42344 active against avian H5N1 PB2; Phase 2a results expected H2 2024","bullets":["In vitro studies show CC-42344 inhibits the PB2 protein of avian influenza A (H5N1) strain from infected dairy cattle.","Phase 2a clinical trial of oral CC-42344 in influenza A subjects ongoing; topline results expected in second half of 2024.","CC-42344 binds to highly conserved PB2 region; high barrier to resistance and broad-spectrum activity highlighted.","CDC reports first human H5N1 cases from dairy cows; company notes no FDA-approved vaccine for humans against this strain.","Positive Phase 1 safety/tolerability data reported in 2022; structure-based platform used to confirm binding."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-024430","json":"https://secwatch.observer/filing/0001493152-24-024430.json","markdown":"https://secwatch.observer/filing/0001493152-24-024430.md","text":"https://secwatch.observer/filing/0001493152-24-024430.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224024430/0001493152-24-024430-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224024430/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T03:20:26.134902+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}